Related Experiment Video
Updated: Aug 30, 2025
08:53
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
906
Compounded Medications and Probiotics for Irritable Bowel Syndrome
Katherine Rivera Nárvaez1, Tara Thompson2
1Revelation Pharma Corporation, Kennesaw, Georgia.
International Journal of Pharmaceutical Compounding
|September 2, 2022
Summary
Individuals with irritable bowel syndrome and ulcerative colitis show altered gut microflora. Pharmaceutical compounding offers targeted therapies and customized dosages for these conditions, addressing imbalances in gut bacteria.
Area of Science:
- Gastroenterology
- Microbiology
- Pharmaceutical Sciences
Background:
- Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC) are associated with distinct gut microflora profiles compared to healthy individuals.
- Alterations include decreased beneficial bacteria, increased pathogenic bacteria, and potential small intestinal bacterial overgrowth (SIBO).
Purpose of the Study:
- To discuss the role of gut microflora in IBS and UC.
- To highlight the significance of pharmaceutical compounding in managing these gastrointestinal disorders.
Main Methods:
- Review of existing studies on gut microflora in IBS and UC.
- Analysis of the therapeutic potential of pharmaceutical compounding for IBS and UC.
Main Results:
- Significant differences in microflora composition are observed in patients with IBS and UC.
- Pharmaceutical compounding can provide targeted treatments and specific dosages not readily available commercially.
Conclusions:
- Gut microflora dysbiosis is a key factor in IBS and UC pathogenesis.
- Compounded medications represent a valuable therapeutic option for personalized management of IBS and UC.
More Related Videos
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
301
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
301
01:17Drugs for Treatment of Diarrhea-Predominant IBS
275
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
275
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
277
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
277
01:17Irritable Bowel Syndrome I: Introduction
353
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
353
01:29Inflammatory Bowel Disease IV: Pharmacological Management
174
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
174
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
398
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
398